Skip to main content
STIM logo

STIM · Neuronetics, Inc. · Documents

Track STIM — free
$1.37 -0.02 (-1.44%) Q1 2026 earnings call transcript
Market Cap
$108.04M
Shares
77.73M
Volume · Nov 13 16.26M Avg daily vol (3M) 1.64M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $149.16M up 99.2% 10-K filed Mar 17, 2026 Quarterly report FY2026 Q3 Revenue $41.96M up 12.5% 10-Q filed Nov 4, 2026 Latest results Revenue rises 12.5%, adjusted EBITDA turns positive 8-K filed Nov 4, 2026 Earnings call Q1 2026 earnings call Held May 5, 2026
2026
Nov 12
Current report 8-K/A Events of Nov 10
Amendment refiles legal opinion for 18,750,000-share offering

Neuronetics amended its report solely to refile a legal opinion and consent that superseded and replaced the originals. The underlying offering covered 18,750,000 common shares at $1.60 per share.

Entered into a material agreement, Other events
2 source passages
Neuronetics, Inc. (the “Company”) is filing this Amendment No. 1 to its Current Report on Form 8-K, originally filed with the Securities and Exchange Commission on November 12, 2026 (the “Original 8-K”), solely to re-file Exhibit 5.1 and Exhibit 23.1 (included in Exhibit 5.1) to the Original 8-K, which supersede and replace in their entirety Exhibits 5.1 and 23.1 to the Original 8-K. On November 10, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (“William Blair”), as representative of the underwriters named in Schedule I attached thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 18,750,000 shares (the “Firm Securities”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price to the public of $1.60 per share (the “Offering”). Open the document at this passage
Nov 12
Current report 8-K Events of Nov 10
18,750,000-share offering priced at $1.60 per share

Neuronetics, Inc. priced an offering of 18,750,000 common shares at $1.60 per share, expecting approximately $27.7 million in net proceeds. It will use part of the proceeds to repay Perceptive Credit Holdings IV, LP term loans and for general corporate purposes.

Entered into a material agreement, Other events Read from the first part of this long document
3 source passages
On November 10, 2026, Neuronetics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with William Blair & Company, L.L.C. (“William Blair”), as representative of the underwriters named in Schedule I attached thereto (collectively, the “Underwriters”), pursuant to which the Company agreed to issue and sell 18,750,000 shares (the “Firm Securities”) of the Company’s common stock, par value $0.01 per share (“Common Stock”), at a price to the public of $1.60 per share (the “Offering”). The Company estimates that the net proceeds to the Company from the Offering, after deducting underwriting discounts and commissions and estimated offering expenses, will be approximately $27.7 million (or $31.9 million if the Underwriters’ option to purchase the Optional Securities is exercised in full). The Company intends to use a portion of the net proceeds from the Offering to repay a portion of the outstanding term loans under the Credit Agreement and Guaranty, as amended, with Perceptive Credit Holdings IV, LP (the “Perceptive Facility”), and for general corporate purposes, including but not limited to sales and marketing, research and development activities, financing of potential acquisitions or establishment of healthcare practices, purchases of inventory, general and administrative matters, working capital and capital expenditures. Open the document at this passage
Nov 10
Current report 8-K Events of Nov 5
Credit amendment requires $15,000,000 prepayment and modifies revenue covenants

Neuronetics, Inc. entered Amendment No. 6 on November 5, 2026, modifying revenue covenants, conditional on a prepayment of no less than $15,000,000. Unless conditions are satisfied or waived by November 30, 2026, the amendment automatically terminates.

Entered into a material agreement
3 source passages
On November 5, 2026, the Company entered into Amendment No. 6 to Credit Agreement and Guaranty by and between the Company, as borrower, and Perceptive, in its capacities as administrative agent for the lender parties thereto and majority lender (the “Perceptive Sixth Amendment”). The Perceptive Sixth Amendment amends the Existing Credit Agreement to, among other things, modify certain revenue covenants, subject to the satisfaction of certain conditions, including, among other things, an optional prepayment in an amount equal to no less than $15,000,000, together with all accrued but unpaid interest and the applicable early prepayment fee, plus the applicable amendment fee and the lender parties’ other costs and expenses. Notwithstanding anything to the contrary contained herein, if the conditions precedent set forth in this Section 2.01 have not been satisfied or waived by the Administrative Agent on or prior to November 30, 2026, then this Amendment shall automatically terminate and be of no further force or effect. Open the document at this passage
Nov 4
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises, but March 2027 covenant creates going-concern doubt

Neuronetics reported third-quarter revenue of $42.0 million, up 13%, and a $1.6 million net loss, but projected March 31, 2027 trailing revenue below its covenant minimum creates substantial going-concern doubt.

Revenue $41.96M ▲ 12.5% Net loss $1.69M Diluted EPS -$0.02
Read from the MD&A section
4 source passages
Total revenue for the three months ended September 30, 2026 was $42.0 million, an increase of $4.7 million, or 13%, compared to the three months ended September 30, 2025 revenue of $37.3 million. We incurred net losses of $1.6 million and $15.8 million for the three and nine months ended September 30, 2026, respectively compared to net losses of $9.4 million and $31.9 million for three and nine months ended September 30, 2025, respectively. The Company currently projects trailing twelve-month revenue for the period ended March 31, 2027 to be below the minimum required revenue for that period as stated in the credit facility agreement. Therefore, substantial doubt exists about the Company’s ability to continue as a going concern. Open the document at this passage
Nov 4
Current report 8-K
Revenue rises 12.5%, adjusted EBITDA turns positive

Neuronetics reported third-quarter 2026 revenue of $42.0 million, up 12.5%, and adjusted EBITDA of $1.9 million versus $(4.7) million last year. Net loss was $1.6 million, and full-year revenue guidance remained $160 million and $164 million.

Financial results, Regulation FD disclosure Read from the first part of this long document
5 source passages
Neuronetics Reports Third Quarter 2026 Financial and Operating Results Total revenue increased 12.5% year-over-year to $42.0 million Adjusted EBITDA of $1.9 million compared to $(4.7) million in the third quarter of 2025 Net loss of $1.6 million compared to a loss of $9.4 million in the third quarter of 2025 Total revenue between $160 million and $164 million, unchanged compared to prior guidance Open the document at this passage
Aug 11
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $41.57M ▲ 9.1% Net loss $3.44M Diluted EPS -$0.05
May 5
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $34.45M ▲ 7.8% Net loss $10.79M Diluted EPS -$0.16
Apr 9
Proxy statement DEF 14A Meeting May 28, 2026
Proxy statement AI summary on its way
Mar 17
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $149.16M ▲ 99.2% Net loss $39M Diluted EPS -$0.59
2025
Mar 27
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $74.89M ▲ 5.0% Net loss $43.71M Diluted EPS -$1.38
2024
Showing 1–50 of 208 documents
Key facts CIK 1227636 CUSIP 64131A105 13F (30d) 68 filings 55 filers Visit website